Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
NAB Plans to Cut 170 Jobs While Expanding Offshore Operations 
Innate Pharma Reports 55% Revenue Drop and €49.2M Net Loss for 2025 
Reflection AI Eyes $25 Billion Valuation in Massive $2.5 Billion Funding Round 
Merck's $6 Billion Bid for Terns Pharma Signals Bold Oncology Push 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Rio Tinto's Resolution Copper Mine: U.S. Smelting Challenges and Global Operations Update 
Google's TurboQuant Algorithm Sends Memory Chip Stocks Tumbling 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
9 Tips for Avoiding Tax Season Cyber Scams 
OpenAI Pulls the Plug on Sora, Ending $1 Billion Disney Partnership 
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns 
Berkshire Hathaway and Tokio Marine Form Major Strategic Insurance Partnership 
FDA Warns Novo Nordisk Over Misleading Ozempic Ad Claims 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SLMG Beverages Eyes Price Hikes Amid Rising Packaging Costs and India's Booming Soft Drink Market 
Patients who lost weight with Eli Lilly's weight-loss drug, Zepbound, eventually regained a significant amount of weight after discontinuing the treatment. These findings were published in the journal JAMA. Shed light on the challenges faced by individuals seeking long-term weight management solutions.
Weight Regain Among Obese Patients
Reuters reported that the study showed that patients with obesity and no diabetes experienced a 14% weight regain nearly a year after transitioning from an eight-month course of Zepbound to a placebo. However, patients who continued the treatment witnessed an additional 5.5% reduction in weight during the 52 weeks.
Sold under the brand name Zepbound for weight loss and known as Mounjaro for type 2 diabetes, Lilly's tirzepatide has emerged as a viable option for individuals struggling with weight management. Tirzepatide, along with Novo Nordisk's Wegovy and Ozempic, belongs to a class of obesity and weight loss treatments that target the GLP-1 hormone.
Risks of Discontinuing Weight-Loss Drugs
Patients who discontinue the use of weight-loss drugs, such as Wegovy, risk regaining their original body weight within approximately five years, as per Bloomberg. Individuals must consider extended therapy with GLP-1 drugs to maximize the long-term benefits of such treatments.
Analysts have underscored the need for extended data evaluation to assess the effects of tirzepatide and other incretin-based therapies after multiple years of continuous treatment. It is essential to gain insights into potential rapidly diminishing responses to these drugs, ensuring better understanding and managing patient weight.
Throughout the 88-week treatment period, patients who continued taking Lilly's drug showcased an impressive 25.3% reduction in weight. In contrast, patients who switched to a placebo after 56 weeks experienced an overall weight reduction of 9.9% during the entire study period.
GLP-1 receptor agonists, including those offered by Novo Nordisk and Eli Lilly, have demonstrated efficacy in inducing a feeling of fullness after eating and slowing gastric emptying. These drugs present a promising approach to address the challenges individuals face in striving for effective weight management.
Photo: Towfiqu barbhuiya/Unsplash
